Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of LBL-003 in advanced malignancies
NCT05042908Phase 1Completed
- Sponsor
- Leads Biolabs
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LBL-003 in advanced malignant solid tumor, sponsored by Leads Biolabs. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Dose-Limiting Toxicities at 4 weeks. Started Dec 2021; status: completed.
02
Drugs
LBL-003
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05042908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042908.